ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]-1-isoquinolinone. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

18 träffar

Bibliografisk träff 2024-08-20

Discovery of Pyrazolo[1,5-a]pyridine Derivatives as Potent and Selective PI3Kγ/δ Inhibitors.

Wang C, Zou F, Qi Z, Liu Q, Shen L, Yuan X, Deng M, Wang A, Wang B, Wang L, Liang X, Liu Q, Liu J.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.4c00817

Bibliografisk träff 2024-06-19

Designing Small Molecule PI3Kγ Inhibitors: A Review of Structure-Based Methods and Computational Approaches.

Yin X, Wang J, Ge M, Feng X, Zhang G.

J Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.1021/acs.jmedchem.4c00347

Bibliografisk träff 2024-01-23

Targeting autophagy drug discovery: Targets, indications and development trends.

Jiang M, Wu W, Xiong Z, Yu X, Ye Z, Wu Z.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2023.116117

Bibliografisk träff 2023-12-20

Discovery of pyrazolo[3,4-d]pyrimidines as novel mitogen-activated protein kinase kinase 3 (MKK3) inhibitors.

Takarada JE, Cunha MR, Almeida VM, Vasconcelos SNS, Santiago AS, Godoi PH, Salmazo A, Ramos PZ, Fala AM, de Souza LR, Da Silva IEP, Bengtson MH, Massirer KB, Couñago RM.

Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2023.117561

Bibliografisk träff 2023-09-01

Discovery of Pyrazolo[1,5-a]pyrimidine derivative as a potent and selective PI3Kγ/δ dual inhibitor.

Liang X, Deng M, Zou F, Qi Z, Wang C, Liu J, Liu Q, Wang B, Qi S, Ge J, Yu H, Wang A, Liu Q, Liu J.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2023.115768

Bibliografisk träff 2023-07-19

A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.

Sutherland JJ, Yonchev D, Fekete A, Urban L.

Nat Commun · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41467-023-40064-9

Bibliografisk träff 2023-03-30

Design, synthesis and bioactivity evaluation of a series of quinazolinone derivatives as potent PI3Kγ antagonist.

Liang Y, Zheng Y, Yang J, Ke J, Cheng K.

Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2023.117261

Bibliografisk träff 2022-11-28

Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents.

Occhiuzzi MA, Lico G, Ioele G, De Luca M, Garofalo A, Grande F.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2022.114971

Bibliografisk träff 2022-07-13

Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.

Liu K, Zheng W, Chen Y, Tang M, Li D, Deng D, Yang T, Zhang C, Liu J, Yuan X, Shi M, Li X, Guo Y, Zhou Y, Zhao M, Chen L.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.2c00568

Bibliografisk träff 2021-01-24

FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.

Wang S, Yuan XH, Wang SQ, Zhao W, Chen XB, Yu B.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2021.113218

Bibliografisk träff 2019-08-06

Discovery of 4-Methylquinazoline Based PI3K Inhibitors for the Potential Treatment of Idiopathic Pulmonary Fibrosis.

Lin S, Jin J, Liu Y, Tian H, Zhang Y, Fu R, Zhang J, Wang M, Du T, Ji M, Wu D, Zhang K, Sheng L, Li Y, Chen X, Xu H.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.9b00969

Bibliografisk träff 2019-05-08

Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.

Jia H, Dai G, Su W, Xiao K, Weng J, Zhang Z, Wang Q, Yuan T, Shi F, Zhang Z, Chen W, Sai Y, Wang J, Li X, Cai Y, Yu J, Ren P, Venable J, Rao T, Edwards JP, Bembenek SD.

J Med Chem · journal article · DOI 10.1021/acs.jmedchem.8b02014

Bibliografisk träff 2018-12-24

Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases.

Perry MWD, Abdulai R, Mogemark M, Petersen J, Thomas MJ, Valastro B, Westin Eriksson A.

J Med Chem · review; journal article · DOI 10.1021/acs.jmedchem.8b01298

Bibliografisk träff 2018-12-04

Targeting the immunity protein kinases for immuno-oncology.

Yuan X, Wu H, Bu H, Zhou J, Zhang H.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2018.11.072

Bibliografisk träff 2018-09-12

Piperidinyl-embeded chalcones possessing anti PI3Kδ inhibitory properties exhibit anti-atopic properties in preclinical models.

Dumontet C, Beck G, Gardebien F, Haudecoeur R, Mathé D, Matera EL, Tourette A, Mattei E, Esmenjaud J, Boyère C, Nurisso A, Peuchmaur M, Pérès B, Bouchaud G, Magnan A, Monneret G, Boumendjel A.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2018.09.033

Bibliografisk träff 2016-10-26

Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies.

Deng C, Lipstein MR, Scotto L, Jirau Serrano XO, Mangone MA, Li S, Vendome J, Hao Y, Xu X, Deng SX, Realubit RB, Tatonetti NP, Karan C, Lentzsch S, Fruman DA, Honig B, Landry DW, O'Connor OA.

Blood · research-article; journal article · DOI 10.1182/blood-2016-08-731240

Bibliografisk träff 2016-08-02

Discovery of a Series of 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-ones as Selective PI3K-δ/γ Inhibitors.

Ferguson FM, Ni J, Zhang T, Tesar B, Sim T, Kim ND, Deng X, Brown JR, Zhao JJ, Gray NS.

ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/acsmedchemlett.6b00209

Bibliografisk träff 2016-07-27

Evolution of a Novel, Orally Bioavailable Series of PI3Kδ Inhibitors from an Inhaled Lead for the Treatment of Respiratory Disease.

Amour A, Barton N, Cooper AW, Inglis G, Jamieson C, Luscombe CN, Morrell J, Peace S, Perez D, Rowland P, Tame CJ, Uddin S, Vitulli G, Wellaway N.

J Med Chem · journal article · DOI 10.1021/acs.jmedchem.6b00799

Gå till forskningen.

Publikationer i urvalet

Discovery of Pyrazolo[1,5-<i>a</i>]pyridine Derivatives as Potent and Selective PI3Kγ/δ Inhibitors.

Designing Small Molecule PI3Kγ Inhibitors: A Review of Structure-Based Methods and Computational Approaches.

Targeting autophagy drug discovery: Targets, indications and development trends.

Discovery of pyrazolo[3,4-d]pyrimidines as novel mitogen-activated protein kinase kinase 3 (MKK3) inhibitors.

Discovery of Pyrazolo[1,5-a]pyrimidine derivative as a potent and selective PI3Kγ/δ dual inhibitor.

A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.

Design, synthesis and bioactivity evaluation of a series of quinazolinone derivatives as potent PI3Kγ antagonist.

Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents.

Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.

FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.

Discovery of 4-Methylquinazoline Based PI3K Inhibitors for the Potential Treatment of Idiopathic Pulmonary Fibrosis.

Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.

Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases.

Targeting the immunity protein kinases for immuno-oncology.

Piperidinyl-embeded chalcones possessing anti PI3Kδ inhibitory properties exhibit anti-atopic properties in preclinical models.

Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies.

Discovery of a Series of 5,11-Dihydro-6<i>H</i>-benzo[<i>e</i>]pyrimido[5,4-<i>b</i>][1,4]diazepin-6-ones as Selective PI3K-δ/γ Inhibitors.

Evolution of a Novel, Orally Bioavailable Series of PI3Kδ Inhibitors from an Inhaled Lead for the Treatment of Respiratory Disease.